Why the study?
Data on outcomes of ViV-TPVI using SAPIEN 3 are limited, and TPVI carries a risk of collapse in patients with severe heart failure.
Answers are grounded in this paper and cite their sources.
This case report demonstrates the feasibility of using the SAPIEN 3 valve for valve-in-valve pulmonary valve implantation in a high-risk patient with severe biventricular heart failure.
Objective: Transcatheter valve-in-valve pulmonary valve implantation (ViV-TPVI) with SAPIEN 3 (Edwards Lifesciences, Irvine, CA, USA) is effective for treating insufficient prosthetic valves in right ventricular outflow tract diseases. SAPIEN 3 is primarily used to replace failed aortic valves; therefore, there is limited published data on the outcomes of its use for ViV-TPVI. In patients with severe heart failure, every procedure can lead to collapse during TPVI. This case report aims to describe the procedural strategy, perioperative management, and short-term outcomes of ViV-TPVI with SAPIEN 3 in a patient with biventricular heart failure, where careful preparation and prerisk assessment were critical to procedural success.
No takes yet. Share an insight, caveat, or question.
Shima et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: